公开(公告)号：WO2005054204A3

公开(公告)日：2005-09-15

申请号：PCT/US2004039597

申请日：2004-11-24

Applicant: SYNCHRONY BIOSCIENCES INC ,  CONNELLY PATRICK R ,  CONNELLY GREGORY P ,  MAGEE ANDREW S

Inventor： CONNELLY PATRICK R ,  CONNELLY GREGORY P ,  MAGEE ANDREW S

IPC: C07D231/12 ,  C07D231/14 ,  C07D261/08 ,  C07D275/02 ,  C07D307/58 ,  A61K31/34 ,  A61K31/415 ,  A61K31/42 ,  A61P39/06

CPC classification number: C07D231/12 ,  C07D231/14 ,  C07D261/08 ,  C07D275/02 ,  C07D307/33 ,  C07D307/58

Abstract: The invention relates to a class of polycyclic compounds that reacts with and neutralizes a reactive oxygen species, such as a free oxygen radical, in a patient and which can then be regenerated back to their original reactive chemical form by a naturally occurring enzyme in said patient. These compounds are useful to treat diseases in a patient characterized by a reactive oxygen species. Moreover, because these compounds can be regenerated back to their original, reactive chemical state in vivo, a single molecule can neutralize multiple molecules of the reactive species. This allows for the use of lower dosages for the treatment of disease, as compared to compounds presently used to treat that same disease, thus avoiding side effects associated with higher dosages.

Abstract translation: 本发明涉及一类在患者中反应并中和活性氧物质例如游离氧自由基的多环化合物，然后可以通过天然存在的酶在所述患者中再生回其原始的反应性化学形式 。 这些化合物可用于治疗以活性氧为特征的患者中的疾病。 此外，由于这些化合物可以在体内再生回到其原始的反应性化学状态，所以单个分子可以中和反应性物质的多个分子。 与目前用于治疗相同疾病的化合物相比，这允许使用较低剂量用于治疗疾病，因此避免与较高剂量相关的副作用。

公开(公告)号：WO2005072142A2

公开(公告)日：2005-08-11

申请号：PCT/US2005001252

申请日：2005-01-14

Applicant: BIOMED SOLUTIONS LLC ,  WEINER MICHAEL ,  CONNELLY PATRICK ,  GEBERT CAROL ,  GRAY ROBERT ,  CUSTER ANDREW

Inventor： WEINER MICHAEL ,  CONNELLY PATRICK ,  GEBERT CAROL ,  GRAY ROBERT ,  CUSTER ANDREW

IPC: C12M1/34 ,  C12Q1/68 ,  G01N33/542 ,  G01N33/58

CPC classification number: G01N33/542 ,  B82Y5/00 ,  B82Y10/00 ,  B82Y15/00 ,  C12Q1/68 ,  C12Q1/6834 ,  G01N33/58 ,  C12Q2563/155 ,  C12Q2563/137 ,  C12Q2523/301

Abstract: A detection device comprised of a hybrid nucleic acid assembly. The device further comprises a nucleic acid polymer, a first nanoparticle conjugated to the nucleic acid polymer, a second nanoparticle conjugated with the nucleic acid polymer, a means for introducing energy into the first nanoparticle, means for detecting energy from the second nanoparticle, and means for determining a physical property of the nucleic acid polymer, wherein the means of introducing energy into the first nanoparticle is a source of mechanical energy.

Abstract translation: 一种由杂交核酸组合物组成的检测装置。 该装置还包括核酸聚合物，与核酸聚合物缀合的第一纳米颗粒，与核酸聚合物缀合的第二纳米颗粒，用于将能量引入第一纳米颗粒的装置，用于检测来自第二纳米颗粒的能量的装置，以及装置 用于确定核酸聚合物的物理性质，其中将能量引入第一纳米颗粒的手段是机械能的来源。

公开(公告)号：WO2005054204A2

公开(公告)日：2005-06-16

申请号：PCT/US2004/039597

申请日：2004-11-24

Applicant: SYNCHRONY BIOSCIENCES, INC. ,  CONNELLY, Patrick, R. ,  CONNELLY, Gregory, P. ,  MAGEE, Andrew, S.

Inventor： CONNELLY, Patrick, R. ,  CONNELLY, Gregory, P. ,  MAGEE, Andrew, S.

IPC: C07D231/12

CPC classification number: C07D231/12 ,  C07D231/14 ,  C07D261/08 ,  C07D275/02 ,  C07D307/33 ,  C07D307/58

Abstract: The invention relates to a class of compounds that reacts with and neutralizes a reactive oxygen species, such as a free oxygen radical, in a patient and which can then be regenerated back to their original reactive chemical form by a naturally occurring enzyme in said patient. These compounds are useful to treat diseases in a patient characterized by a reactive oxygen species. Moreover, because these compounds can be regenerated back to their original, reactive chemical state in vivo, a single molecule can neutralize multiple molecules of the reactive species. This allows for the use of lower dosages for the treatment of disease, as compared to compounds presently used to treat that same disease, thus avoiding side effects associated with higher dosages.

Abstract translation: 本发明涉及一类在患者体内与活性氧物质例如游离氧自由基反应并中和的化合物，然后可以通过所述患者中天然存在的酶将其再生回到其原始的反应性化学形式。 这些化合物可用于治疗以活性氧为特征的患者中的疾病。 此外，由于这些化合物可以在体内再生回到其原始的反应性化学状态，所以单个分子可以中和反应性物质的多个分子。 与目前用于治疗相同疾病的化合物相比，这允许使用较低剂量用于治疗疾病，因此避免与较高剂量相关的副作用。

公开(公告)号：WO2005000696A1

公开(公告)日：2005-01-06

申请号：PCT/GB2004/002780

申请日：2004-06-28

Applicant: FLEXIPOL PACKAGING LTD ,  SMITH, Ian, John ,  GRIFFITHS, John, Joseph, Dermot ,  CONNELLY, Patrick, Thomas ,  BRASSINGTON, Paul, Stuart

Inventor： SMITH, Ian, John ,  GRIFFITHS, John, Joseph, Dermot ,  CONNELLY, Patrick, Thomas ,  BRASSINGTON, Paul, Stuart

IPC: B65D30/08

CPC classification number: B65D33/004 ,  B65D31/04 ,  B65D33/22

Abstract: The invention relates to plastic bags and sack for use especially in the food and pharmaceutical industries. The bag (2) comprises inner and outer bag sections (4, 14) which are joined at least at an upper portion in a manner which allows them to be separated when required, such as by heat sealing. The outer bag section (14) may be provided with a mouth (10) through which the inner bag section can be withdrawn when required. Alternatively, the outer bag section may be peeled away from the inner bag section. The inner bag section is heat sealed after filling with contents to retain the contents in the inner portion. The heat sealing step also serves to secure the bag sections together as above. The inner bag section is preferably provided with a closeable mouth (132) separate from the end by which it is filled, through which the contents may be dispensed.

Abstract translation: 本发明涉及特别用于食品和制药行业的塑料袋和袋。 袋子（2）包括内部和外部袋部分（4,14），它们至少在上部部分以允许它们在需要时被分离的方式，例如通过热封。 外袋部分（14）可以设置有口（10），当需要时可以将内袋部分抽出。 或者，外袋部分可以从内袋部分剥离。 内袋部分在填充内容物之后被热密封，以将内容物保持在内部。 热封步骤还用于将袋部分固定在一起如上。 内袋部优选地设置有与其被填充的端部分离的可关闭的口（132），通过该口可以分配内容物。

公开(公告)号：WO2003101534A1

公开(公告)日：2003-12-11

申请号：PCT/US2003/017610

申请日：2003-06-04

Applicant: BIOPHAN TECHNOLOGIES, INC. ,  HELFER, Jeffrey, L. ,  WEINER, Michael, L. ,  CONNELLY, Patrick, R. ,  MAcDONALD, Stuart, G.

Inventor： HELFER, Jeffrey, L. ,  WEINER, Michael, L. ,  CONNELLY, Patrick, R. ,  MAcDONALD, Stuart, G.

IPC: A61N1/18

CPC classification number: A61N1/37 ,  A61B5/0215 ,  A61B5/055 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1459 ,  A61B5/7203 ,  A61B2562/02 ,  A61B2562/0233 ,  A61B2562/046 ,  A61B2562/222 ,  A61B2562/223 ,  A61N1/3718 ,  G01R33/285

Abstract: An implantable nuclear magnetic resonance spectrometer comprised of a first input lead and a second output lead, wherein each of said first input lead and said second output lead comprise a photonic lead (585).

Abstract translation: 一种可植入核磁共振光谱仪，包括第一输入引线和第二输出引线，其中所述第一输入引线和所述第二输出引线中的每一个包括光子引线（585）。

公开(公告)号：WO03001887A3

公开(公告)日：2003-08-21

申请号：PCT/US0220567

申请日：2002-06-28

Applicant: ESSENTIAL THERAPEUTICS INC ,  PLIVA D D ,  MOE SCOTT T ,  ALA PAUL J ,  PEROLA EMANUELE ,  FAERMAN CARLOS H ,  CLEMENT JACOB J ,  ALI JANID A ,  WILL PAUL M ,  MARCHESE SALVATORE A ,  MAGEE ANDREW S ,  GAZZANIGA JOHN V ,  FARADY CHRISTOPHER ,  NAVIA MANUEL A ,  CONNELLY PATRICK R

Inventor： MOE SCOTT T ,  ALA PAUL J ,  PEROLA EMANUELE ,  FAERMAN CARLOS H ,  CLEMENT JACOB J ,  ALI JANID A ,  WILL PAUL M ,  MARCHESE SALVATORE A ,  MAGEE ANDREW S ,  GAZZANIGA JOHN V ,  FARADY CHRISTOPHER ,  NAVIA MANUEL A ,  CONNELLY PATRICK R

IPC: A61K31/519 ,  A61K31/525 ,  A61P31/04 ,  C07D401/12 ,  C07D471/04 ,  C07D475/08 ,  C07D487/02 ,  C07D487/04 ,  C07D519/00 ,  A61K31/517

CPC classification number: C07D401/12 ,  C07D471/04 ,  C07D475/08 ,  C07D487/04

Abstract: The invention is based on the discovery of a new class of heterocyclic compounds having, for example, antibacterial properties. The D-Ala-D-Ala ligase enzyme is a critical pathway enzyme in the bacterial cell-wall synthesis. The compounds can bind to and inhibit the enzyme D-Ala-D-Ala ligase. The new compounds' activity combined with their ability to cross bacterial cell membranes makes them suitable for use as antibacterial drugs or other antibacterial applications.

Abstract translation: 本发明基于发现具有例如抗菌性质的新类型的杂环化合物。 D-Ala-D-Ala连接酶是细菌细胞壁合成中的关键途径酶。 该化合物可以结合并抑制酶D-Ala-D-Ala连接酶。 新化合物的活性与其交叉细菌细胞膜的能力相结合，使其适合用作抗菌药物或其他抗菌药物。

公开(公告)号：WO2003031561A1

公开(公告)日：2003-04-17

申请号：PCT/US2002/032231

申请日：2002-10-09

Applicant: BIOMED SOLUTIONS, LLC ,  WEINER, Michael, L. ,  CONNELLY, Patrick, R. ,  GEBERT, Carol ,  GRAY, Robert, W.

Inventor： WEINER, Michael, L. ,  CONNELLY, Patrick, R. ,  GEBERT, Carol ,  GRAY, Robert, W.

IPC: C12M1/34

CPC classification number: C12Q1/68 ,  C12Q1/6816 ,  C12Q1/6818 ,  C12Q2565/101 ,  C12Q2563/155 ,  C12Q2563/113

Abstract: A detection device containing a hybrid nucleic acid assembly. The device contains a nucleic acid polymer, a first complementary oligonucleotide annealed to a first consensus sequence on the nucleic acid polymer, a second complementary oligonucleotide annealed to a second consensus sequence on the nucleic acid polymer, a first nanoparticle conjugated with the first complementary oligonucleotide, a second nanoparticle conjugated with the second complementary oligonucleotide, means for introducing energy into the first nanoparticle, means for withdrawing energy from the second nanoparticle, means for detecting the withdrawal of energy from the second nanoparticle, and means for determining a physical property of the nucleic acid polymer while energy is introduced into the first nanoparticle.

Abstract translation: 一种含有杂交核酸组件的检测装置。 该装置含有核酸聚合物，退火于核酸聚合物上的第一共有序列的第一互补寡核苷酸，退火至核酸聚合物上的第二共有序列的第二互补寡核苷酸，与第一互补寡核苷酸缀合的第一纳米颗粒， 与第二互补寡核苷酸缀合的第二纳米颗粒，用于将能量引入第一纳米颗粒的装置，用于从第二纳米颗粒中提取能量的装置，用于检测来自第二纳米颗粒的能量抽出的装置，以及用于确定核酸的物理性质的装置 酸性聚合物，同时将能量引入第一纳米颗粒。

公开(公告)号：WO2003011386A1

公开(公告)日：2003-02-13

申请号：PCT/US2002/023892

申请日：2002-07-29

Applicant: BIOMED SOLUTIONS, LLC ,  CONNELLY, Patrick, R. ,  MACDONALD, Stuart, G. ,  GRAY, Robert, W. ,  GEBERT, Carol

Inventor： CONNELLY, Patrick, R. ,  MACDONALD, Stuart, G. ,  GRAY, Robert, W. ,  GEBERT, Carol

IPC: A61M37/00

CPC classification number: A61B5/0084 ,  A61B5/0071 ,  A61B5/076 ,  A61B5/145 ,  A61B5/150015 ,  A61B5/150221 ,  A61B5/150229 ,  A61B5/417 ,  A61F2/82 ,  A61M1/3621 ,  A61M1/3679 ,  A61M1/3687 ,  A61M1/38 ,  G01N15/10 ,  G01N2015/1006 ,  G01N2015/149

Abstract: A flow cytometer (44) containing a device for sampling cellular material within a body, comprising a detector (86), controller (88), light source (84) and injector (96). The flow cytometer (44) is adapted to mark cells within bodily fluid with a marker to produce marked cells, to analyze the marked cells, to sort the cells within the bodily fluid to produce sorted cells, and to maintain the sorted cells in a viable state.

Abstract translation: 一种流式细胞仪（44），其包含用于在体内采样细胞材料的装置，包括检测器（86），控制器（88），光源（84）和注射器（96）。 流式细胞仪（44）适于用标记物标记体液中的细胞以产生标记的细胞，分析标记的细胞，对体液内的细胞进行分类以产生分选的细胞，并将分选的细胞维持在可行的 州。

公开(公告)号：WO2003011385A1

公开(公告)日：2003-02-13

申请号：PCT/US2002/023780

申请日：2002-07-29

Applicant: BIOMED SOLUTIONS, LLC ,  CONNELLY, Patrick, R. ,  MACDONALD, Stuart, G. ,  GRAY, Robert, W. ,  GEBERT, Carol

Inventor： CONNELLY, Patrick, R. ,  MACDONALD, Stuart, G. ,  GRAY, Robert, W. ,  GEBERT, Carol

IPC: A61M37/00

CPC classification number: A61B5/0084 ,  A61B5/0071 ,  A61B5/076 ,  A61B5/145 ,  A61B5/15003 ,  A61B5/155 ,  A61F2/82 ,  A61M1/3621 ,  A61M1/3679 ,  A61M1/3687 ,  A61M1/38 ,  G01N15/1456 ,  G01N2015/1006 ,  G01N2015/149

Abstract: A flow cytometer (300) containing a device for sampling cellular material (306) within a body. The flow cytometer is adapted to mark cells within bodily fluid (306) with a marker to produce marked cells, to analyze the marked cells, to sort the cells within the bodily fluid to produce sorted cells, to maintain the sorted cells in a viable state, and to remove the marker from the marked cells. Two marker removal devices (320, 324) are used in the flow cytometer.

Abstract translation: 流式细胞仪（300），其包含用于在体内采样细胞材料（306）的装置。 流式细胞仪适于用标记物标记体液（306）中的细胞以产生标记的细胞，分析标记的细胞，对体液内的细胞进行分类以产生分选的细胞，以将分选的细胞维持在可行状态 并从标记的细胞中去除标记物。 在流式细胞仪中使用两个标记物去除装置（320,324）。

公开(公告)号：WO2002072004A3

公开(公告)日：2002-09-19

申请号：PCT/US2002/006794

申请日：2002-03-06

Applicant: BIOPHAN, LLC ,  CONNELLY, Patrick, R. ,  WEINER, Michael, L.

Inventor： CONNELLY, Patrick, R. ,  WEINER, Michael, L.

IPC: C12N5/00

Abstract: An apparatus for regulating the concentration of insulin within the blood of a living organism, wherein said apparatus is comprised of an in vitro cell culture for producing insulin, an in vitro cell culture for producing glucagon, an in vitro cell culture for producing somatostatin, means for measuring the concentration of glucose within the blood of such living organism, means for measuring the concentration of insulin within the blood of such living organism, means for delivering a specified amount of insulin to the blood of such living organism, means for delivering a specified amount of glucagon to the blood of such living organism, means for delivering a specified amount of somatostain to the blood of such living organism, and means for reducing the amount of insulin within such blood of such living organism.